Zarif Hawazen A, Alam Sultan S, Baashar Abdulrahman, Alsharif Abdulaziz, Alhilabi Mashael
Medicine / Endocrinology, Ministry of the National Guard - Health Affairs, King Abdullah International Medical Research Center, Jeddah, SAU.
Internal Medicine, King Saud Bin Abdulaziz University for Health Sciences / King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, SAU.
Cureus. 2020 Jan 21;12(1):e6730. doi: 10.7759/cureus.6730.
Background Graves' disease is the most common cause of thyrotoxicosis. It can be treated using three different modalities, which include anti-thyroid drugs (ATD), radioactive iodine (RAI), and near-total thyroidectomy. This cohort study aimed to assess the treatment modality preferred at King Abdulaziz Medical City (KAMC) and to compare the treatment options in relation to the prognosis of the disease. Methods A retrospective cohort study was conducted on a total of 100 patients with Graves' disease who were treated and followed up in the endocrine clinics at KAMC between January 2013 and December 2018. Data on age at diagnosis, duration of illness, treatment modality, and response to treatment were extracted from paper and electronic medical files and analyzed. Results A total of 100 patients with Graves' disease were included in this cohort study. The ratio of female:male was 2:1. The median age in years was 32 (16). They were treated with ATD (60%), RAI ablation (40%), and none were treated by surgery. The remission rate was 53.3% for patients treated with ATD and 95% for RAI ablation. Hypothyroidism occurred in 90% of the responders to RAI and in 12% that were treated with ATD. Most of the patients that relapsed underwent RAI as the second line of treatment. Their remission rate was 78.6%. Conclusion ATD was the treatment modality mostly used for Graves' disease in our center. It resulted in a remission rate of 53%, which is higher than reported in national studies. Although the rate of remission post RAI ablation was as high as 95%, most patients developed hypothyroidism.
格雷夫斯病是甲状腺毒症最常见的病因。它可以通过三种不同的方式进行治疗,包括抗甲状腺药物(ATD)、放射性碘(RAI)和近全甲状腺切除术。这项队列研究旨在评估阿卜杜勒阿齐兹国王医疗城(KAMC)首选的治疗方式,并比较与疾病预后相关的治疗选择。方法:对2013年1月至2018年12月期间在KAMC内分泌诊所接受治疗和随访的100例格雷夫斯病患者进行回顾性队列研究。从纸质和电子病历中提取诊断时的年龄、病程、治疗方式和治疗反应等数据并进行分析。结果:本队列研究共纳入100例格雷夫斯病患者。女性与男性的比例为2:1。年龄中位数为32岁(范围16岁)。他们接受了ATD治疗(60%)、RAI消融治疗(40%),无人接受手术治疗。接受ATD治疗的患者缓解率为53.3%,接受RAI消融治疗的患者缓解率为95%。接受RAI治疗的缓解者中有90%发生了甲状腺功能减退,接受ATD治疗的患者中有12%发生了甲状腺功能减退。大多数复发患者接受RAI作为二线治疗。他们的缓解率为78.6%。结论:ATD是我们中心治疗格雷夫斯病最常用的治疗方式。其缓解率为53%,高于国内研究报道。尽管RAI消融后的缓解率高达95%,但大多数患者出现了甲状腺功能减退。